In 2023, the per capita expenditure on antiinfective medicines in Sweden was 34 US Dollars. From 2024 onwards, the forecasted data shows a consistent decline over the next five years. In 2024, the value stands at 33 US Dollars per capita. By 2025, this decreases slightly to 31.6 US Dollars per capita, marking a -4.24% year-on-year variation from the previous year. In 2026, the value is further forecasted to drop to 30.4 US Dollars per capita, indicating another -3.80% decline compared to 2025.
For 2027, the per capita expenditure reduces to 29.3 US Dollars, showing a -3.62% year-on-year decrease. Finally, in 2028, the forecasted value is 28.4 US Dollars per capita, a -3.07% reduction from the previous year. Over the last two years of the forecast, the average annual decrease (CAGR) is anticipated to be approximately -3.45% annually.
Future trends to watch for include the potential impact of new medical technologies, changes in healthcare policies, and the emergence of antibiotic resistance. These factors could significantly influence the demand and expenditure on antiinfective medicines in Sweden.
